Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
Wynne D. Smith(Royal Brompton Hospital), Jane C. Davies(Guy's and St Thomas' NHS Foundation Trust), Ronan A. Murphy(Imperial College London), Loren Cameron(Imperial College London), Alain Filloux(Nanyang Technological University), Huw D. Williams(Imperial College London), Jeremy S. Webb(University of Southampton), Andrew Jones(Royal Brompton Hospital), Emmanuelle Bardin(Inserm), Zoltán Takáts(Imperial College London), A R Turnbull(Imperial College London), C. Edmondson(Royal Brompton Hospital), Katie V. Farrant(Imperial College London), Eric W.F.W. Alton(Imperial College London), Gary Connett(Wellcome Trust), Andrew Bush(British Lung Foundation), Jacob G. Bundy(Imperial College London), Saul N. Faust(University Hospital Southampton NHS Foundation Trust), Natasha Wierre-Gore(Imperial College London), Paul S. Freemont(Imperial College London), Odel Soren(University of Southampton)
Cited by 107
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts
|Nature Protocols|2007|2.1k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children
|Pediatric Critical Care Medicine|2020|1.2k
A characterization of DNA release in <i>Pseudomonas aeruginosa</i> cultures and biofilms
|Molecular Microbiology|2005|1.1k